Abiomed (ABMD) Impella Approved for Reimbursement in the Netherlands

May 28, 2013 8:49 AM EDT
Abiomed, Inc. (Nasdaq: ABMD) announced that the Netherlands has approved new reimbursement coding and payment for the Impella product. The new coding allows for hospitals to receive funding for the use of the Impella technology in a broad set of clinical indications of heart disease through the process known as Diagnosis Treatment Combinations (Diagnose Behandeling Combinaties; DBCs), similar to the Medicare Diagnosis-Related Group (DRG) system in the United States.

New reimbursement is a significant milestone for the recognition of Impella as a required therapy for treatment of heart disease in the European hospital setting. The Netherlands has also been a leader in early clinical and cost effectiveness research of the Impella technology under the leadership of Dr. Jose Henriques at the Amsterdam Medical Center.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA